5.86
Quanterix Corp stock is traded at $5.86, with a volume of 973.68K.
It is down -0.17% in the last 24 hours and down -7.28% over the past month.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
See More
Previous Close:
$5.87
Open:
$5.93
24h Volume:
973.68K
Relative Volume:
1.47
Market Cap:
$273.73M
Revenue:
$121.14M
Net Income/Loss:
$-32.33M
P/E Ratio:
-6.814
EPS:
-0.86
Net Cash Flow:
$-22.69M
1W Performance:
-6.84%
1M Performance:
-7.28%
6M Performance:
+35.65%
1Y Performance:
-22.07%
Quanterix Corp Stock (QTRX) Company Profile
Name
Quanterix Corp
Sector
Industry
Phone
617-301-9400
Address
900 MIDDLESEX TURNPIKE, BILLERICA, MA
Compare QTRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
QTRX
Quanterix Corp
|
5.86 | 274.19M | 121.14M | -32.33M | -22.69M | -0.86 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-01-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-08-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| May-23-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-15-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-09-22 | Downgrade | Cowen | Outperform → Market Perform |
| Aug-09-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-02-22 | Upgrade | Goldman | Sell → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-04-21 | Initiated | Goldman | Sell |
View All
Quanterix Corp Stock (QTRX) Latest News
Quanterix at TD Cowen Conference: Strategic Growth and Diagnostics Focus - Investing.com
Quanterix Corporation (NASDAQ:QTRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Quanterix Q4 Earnings Call Highlights - Defense World
Quanterix (QTRX) Revenue Growth Keeps Losses Central To Bulls’ Long-Term Narrative - simplywall.st
Earnings call transcript: Quanterix Q4 2025 shows revenue beat but EPS miss - Investing.com Australia
Quanterix Corp (QTRX) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst Strategic Shifts - GuruFocus
Quanterix Q4 2025 Earnings Call Transcript - MarketBeat
Quanterix Q4 2025 slides: cost cuts drive path to cash flow breakeven - Investing.com South Africa
Quanterix Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Quanterix (QTRX) Exceeds Q4 Revenue Expectations with Strong Per - GuruFocus
Quanterix Corporation (QTRX) Releases Q4 2025 Earnings: Revenue Beats but EPS Slightly Misses - Quiver Quantitative
Quanterix earnings missed by $0.06, revenue topped estimates - Investing.com
Quanterix (NASDAQ:QTRX) Releases Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Quanterix Corporation 8-K Filing Analysis - TradingView
Quanterix Earnings Report: Q4 Overview - Benzinga
Alzheimer’s blood test heads to 15,000 community events a year - Stock Titan
Quanterix (QTRX) Set to Announce Q4 Earnings with Revenue Growth Expected - GuruFocus
Quanterix (QTRX) to Release Earnings on Monday - Defense World
Quanterix Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Earnings Outlook For Quanterix - Benzinga
Quanterix Corp (QTRX) Q4 2025 Earnings Report Preview: What To L - GuruFocus
Quanterix to Participate in Upcoming Investor Conferences - ChartMill
Envestnet Asset Management Inc. Grows Holdings in Quanterix Corporation $QTRX - Defense World
Quanterix (QTRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investors can hear Quanterix 2025 results discussed on Mar. 2 call - Stock Titan
Quanterix (NASDAQ:QTRX) Shares Up 0.7%Time to Buy? - MarketBeat
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer’s Blood Test - Clinical Lab Products
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing - Yahoo Finance
Quanterix submits FDA 510(k) for multi-analyte Alzheimer's blood test - MSN
Aug Swings: Should value investors consider Quanterix CorporationGlobal Markets & Growth Focused Entry Point Reports - baoquankhu1.vn
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test - TradingView
Quanterix (QTRX) Submits Alzheimer's Blood Test for FDA Approval - GuruFocus
Quanterix submits FDA 510(k) for multi-analyte Alzheimer’s blood test - Investing.com
Blood test to spot Alzheimer’s earlier moves to FDA review - Stock Titan
What’s the MACD signal for Quanterix CorporationWeekly Volume Report & Long-Term Growth Stock Strategies - mfd.ru
Quanterix (NASDAQ:QTRX) Trading Down 3.6%Here's What Happened - MarketBeat
Quanterix (NASDAQ:QTRX) Trading Down 3.6% – Here’s What Happened - Defense World
Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing
Study finds multi-biomarker approach improves Alzheimer’s risk assessment - Investing.com
15-year brain study: blood test combo better flags Alzheimer’s risk - Stock Titan
Quanterix Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
The Truth About Quanterix Corp (QTRX): Tiny Biotech, Massive Hype – But Is It Worth Your Money? - AD HOC NEWS
Big Money Moves: Is Quanterix Corporation stock overvalued by current metricsWeekly Trade Analysis & Community Consensus Trade Alerts - Bộ Nội Vụ
Does Quanterix Corporation stock benefit from AI growthWeekly Stock Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Illumina names former NIH official as medical chief; commercial chief joins Quanterix - Seeking Alpha
Canaccord Genuity reiterates Hold rating on Quanterix stock By Investing.com - Investing.com Nigeria
Canaccord Genuity reiterates Hold rating on Quanterix stock - Investing.com
Why Quanterix Corporation stock could rally in 2025July 2025 Selloffs & Risk Controlled Daily Trade Plans - Улправда
How Quanterix Corporation stock compares to market leadersMarket Growth Report & Weekly Market Pulse Updates - Улправда
Quanterix Corp Stock (QTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):